Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive ma...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yoshimoto, Takayuki, Mizoguchi, Izuru, Katagiri, Seiichiro, Tauchi, Tetsuzo, Furusawa, Jun-ichi, Chiba, Yukino, Mizuguchi, Junichiro, Ohyashiki, Junko H, Ohyashiki, Kazuma
Médium: Artigo
Jazyk:Inglês
Vydáno: Landes Bioscience 2014
Témata:
Author's View
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4091524/
https://ncbi.nlm.nih.gov/pubmed/25057448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.28861
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky